Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2013

01-11-2013 | Poster presentation

PB.37: Screen-detected, noncalcified, mammographic lesions with normal or benign ultrasound findings: is stereotactic biopsy necessary?

Authors: D Tzias, S Yusuf, L Wilkinson

Published in: Breast Cancer Research | Special Issue 1/2013

Login to get access

Excerpt

Ultrasound has long been used in the symptomatic service, not only to distinguish cystic from solid masses but also to help in the differentiation of benign from malignant lesions. The ability to correlate a benign ultrasound mass with a mammographic mass eliminates the need for further intervention. We evaluate the need for stereotactic biopsy in screen-detected, nonpalpable lesions without calcification, which have either benign or normal sonographic findings. …
Literature
1.
Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA: Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology. 1995, 196 (1): 123-134.CrossRefPubMed
2.
Lucas-Fehm L: Sonographic mammographic correlation. Applied Radiology. 2005, 34 (2): 20-
Metadata
Title
PB.37: Screen-detected, noncalcified, mammographic lesions with normal or benign ultrasound findings: is stereotactic biopsy necessary?
Authors
D Tzias
S Yusuf
L Wilkinson
Publication date
01-11-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3537

Other articles of this Special Issue 1/2013

Breast Cancer Research 1/2013 Go to the issue

Poster presentation

PB.22: Does the Nottingham predictor of bidimensional product of calcium accurately predict the success of wide local excision for ductal carcinoma in situ surgery in our centre?

Poster presentation

PB.23: Effect of detector type on cancer detection in digital mammography

Poster presentation

PB.02: Magnetic resonance imaging axilla: friend or foe?

Poster presentation

PB.30: What is your biopsy threshold in symptomatic clinic and what should it be? B2:B5 biopsy ratio: 18 months in our centre

Poster presentation

PB.34: Results by letter for low-risk breast biopsies: an audit of current practice at Nottingham Breast Institute

Poster presentation

PB.44: Audit of interval cancers from family history breast screening
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits